RCT of NLP-Based Feedback for Improving SDM in Men with Localized Prostate Cancer
Launched by CEDARS-SINAI MEDICAL CENTER · Feb 26, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help men with localized prostate cancer make better decisions about their treatment. Researchers want to see if using a special feedback system that combines natural language processing and artificial intelligence (NLP+AI) can improve how doctors communicate risks and benefits during treatment consultations. In the trial, 220 patients will be divided into two groups: one group will receive standard information about their treatment options, while the other group will get additional feedback about their consultations within a few days. This feedback will help doctors improve their communication and assist patients in understanding their choices better.
To be eligible for the trial, participants must be male patients who are having their first treatment consultation for localized prostate cancer or are considering a change in treatment after being on active surveillance. They also need to be able to read and write in English. During the study, both patients and doctors will participate in follow-up calls to discuss any questions and clarify information, and they will complete brief surveys about their experiences. This trial aims to understand if the new feedback system can reduce confusion for patients and improve the overall quality of information shared during these important conversations.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Physician Inclusion Criteria (1) Physicians who typically counsel prostate cancer patients (Urology, Radiation Oncology, Medical Oncology)
- • Patient Inclusion Criteria
- • 1. Patients undergoing initial treatment consultation for clinically localized prostate cancer;
- • 2. Patients with upgraded prostate cancer on active surveillance considering conversion to definitive local therapy;
- • 3. Ability to read and write in English.
- Exclusion Criteria:
- • 1. Under 18 years of age;
- • 2. Subjects with difficulty communicating or dementia;
- • 3. Non-English speakers, given that our NLP-based tools cannot be used with languages other than English;
- • 4. Patients with locally advanced or metastatic prostate cancer;
- • 5. Patients who have already been treated for clinically localized prostate cancer.
About Cedars Sinai Medical Center
Cedars-Sinai Medical Center is a renowned nonprofit academic medical center located in Los Angeles, California, recognized for its commitment to patient care, research, and education. As a leading institution in clinical trials, Cedars-Sinai harnesses innovative approaches to advance medical knowledge and improve treatment outcomes across various specialties. With a multidisciplinary team of experts, state-of-the-art facilities, and a patient-centered approach, Cedars-Sinai actively contributes to the development of novel therapies and interventions, ensuring the highest standards of clinical research while prioritizing patient safety and ethical considerations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported